

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>14875-0164US1</b>	Application No. <b>10/582,413</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Toshihiko Ohtomo et al.</b>	
		Filing Date <b>October 26, 2006</b>	Group Art Unit <b>1643</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	1 327 680 A1	07/16/2003	EPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	2	Sekimoto et al., "Eradication of Human Myeloma Cells by a Recombinant HLA Class I-Specific Single Chain Fv Diabody," <i>Blood</i> , 102:932a, XP009106629 (Abstract #3469) (November 2003) [Abstract of the American Society of Hematology 45 <sup>th</sup> Annual Meeting, December 6-9, 2003, San Diego, California]
	3	Sekimoto et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, XP002987122 (Abstract #3474) (November 2003) [Abstract of the American Society of Hematology 45th Annual Meeting, December 6-9, 2003, San Diego, California]

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	